Merchant banker G. Steven Burrill predicts that 2004 will rank among the biggest ever for biotech IPOs, and that drug development partnerships between small biotechs and established drug firms will be a key source of financing (thereby allowing big drug companies to stock their product development pipelines more cheaply and efficiently than by company acquisitions). Burrill says, "They won't buy a company, because they don't need to."
posted by Marcus Zillman |
7:16 PM
